{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:09:39Z","timestamp":1772752179351,"version":"3.50.1"},"reference-count":130,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19). The outbreak of this coronavirus was first identified in Wuhan (Hubei, China) in December 2019, and it was declared as pandemic by the World Health Organization (WHO) in March 2020. Today, several vaccines against SARS-CoV-2 have been approved, and some neutralizing monoclonal antibodies are being tested as therapeutic approaches for COVID-19 but, one of the key questions is whether both vaccines and monoclonal antibodies could be effective against infections by new SARS-CoV-2 variants. Nevertheless, there are currently more than 1000 ongoing clinical trials focusing on the use and effectiveness of antiviral drugs as a possible therapeutic treatment. Among the classes of antiviral drugs are included 3CL protein inhibitors, RNA synthesis inhibitors and other small molecule drugs which target the ability of SARS-COV-2 to interact with host cells. Considering the need to find specific treatment to prevent the emergent outbreak, the aim of this review is to explain how some repurposed antiviral drugs, indicated for the treatment of other viral infections, could be potential candidates for the treatment of COVID-19.<\/jats:p>","DOI":"10.3390\/ph14060503","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T22:02:23Z","timestamp":1621980143000},"page":"503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5197-6570","authenticated-orcid":false,"given":"Luana","family":"Bauso","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Imbesi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"},{"name":"Laboratori Campisi, Corso Vittorio Emanuele 231, 96012 Avola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gasparo","family":"Irene","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Cal\u00ec","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bitto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1097\/01.inf.0000188166.17324.60","article-title":"History and recent advances in coronavirus discovery","volume":"24","author":"Kahn","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/JVI.00080-16","article-title":"Homology-Based identification of a mutation in the coronavirus RNA- dependent RNA polymerase that confers resistance to multiple mutagens","volume":"90","author":"Sexton","year":"2016","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3201\/eid1002.030913","article-title":"Ultrastructural characterization of SARS coronavirus","volume":"10","author":"Goldsmith","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pal, M., Berhanu, G., Desalegn, C., and Kandi, V. (2020). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus, 12.","DOI":"10.7759\/cureus.7423"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/22221751.2020.1725399","article-title":"RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak","volume":"9","author":"Chen","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus infections more than just the common cold","volume":"323","author":"Paules","year":"2020","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Paraskevis, D., Kostaki, E.G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., and Tsiodras, S. (2020). Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol., 79.","DOI":"10.1016\/j.meegid.2020.104212"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"3","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T.M., Raj, V.S., Zaki, A.M., Osterhaus, A.D., Haagmans, B.L., Gorbalenya, A.E., and Snijder, E.J. (2012). Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio, 3.","DOI":"10.1128\/mBio.00473-12"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","article-title":"Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets","volume":"23","author":"Czub","year":"2005","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1128\/JVI.72.8.6838-6850.1998","article-title":"Coronavirus particle assembly: Primary structure requirements of the membrane protein","volume":"72","author":"Kuo","year":"1998","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Virus Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.2014.912134","article-title":"Current advancements and potential strategies in the development of MERS-CoV vaccines","volume":"13","author":"Zhang","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol. Immunol"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.micinf.2020.01.003","article-title":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China","volume":"22","author":"Yu","year":"2020","journal-title":"Microbes Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-virology-100114-055218","article-title":"Continuous and discontinuous RNA synthesis in coronaviruses I","volume":"2","author":"Sola","year":"2015","journal-title":"Ann. Rev. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/3-540-26765-4_3","article-title":"The coronavirus replicase","volume":"287","author":"Ziebuhr","year":"2005","journal-title":"Coronavirus Replication and Reverse Genetics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10900","DOI":"10.1128\/JVI.00385-06","article-title":"Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis","volume":"80","author":"Escors","year":"2006","journal-title":"J. Virol."},{"key":"ref_23","unstructured":"Greenwood, D., Barer, M., Slack, R., and Irving, W. (2012). Coronaviruses. Medical Microbiology, Churchill Livingstone. [18th ed.]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J.C., Muecksch, F., Rutkowska, M., Hoffmann, H.H., and Michailidis, E. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife, 9.","DOI":"10.7554\/eLife.61312"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing activity of BNT162b2-elicited serum-preliminary report","volume":"384","author":"Liu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B.E., de Oliveira, T., Vermeulen, M., and van der Berg, K. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med., in press.","DOI":"10.1101\/2021.01.18.427166"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Liu, Z., VanBlargan, L.A., Bloyet, L.M., Rothlauf, P.W., Chen, R.E., Stumpf, S., Zhao, H., Errico, J.M., Theel, E.S., and Liebeskind, M.J. (2020). Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv, in press.","DOI":"10.1101\/2020.11.06.372037"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","article-title":"SARS-CoV-2 variants and ending the COVID-19 pandemic","volume":"397","author":"Fontanet","year":"2021","journal-title":"Lancet"},{"key":"ref_33","unstructured":"Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C., and Di Napoli, R. (2020). Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls, StatPearls Publishing."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jans, D.A., and Wagstaff, K.M. (2020). Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?. Cells, 9.","DOI":"10.3390\/cells9092100"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wulan, W.N., Heydet, D., Walker, E.J., Gahan, M.E., and Ghildyal, R. (2015). Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.00553"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., and Wagstaff, K.M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res., 178.","DOI":"10.1016\/j.antiviral.2020.104787"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jmv.25709","article-title":"Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV","volume":"92","author":"Liu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Deb, P., Molla, M.M.A., and Rahman, K.M.S. (2021). An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf. Health, in press.","DOI":"10.1016\/j.bsheal.2021.02.001"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Jones, B.E., Brown-Augsburger, P.L., Corbett, K.S., Westendorf, K., Davies, J., Cujec, T.P., Wiethoff, C.M., Blackbourne, J.L., Heinz, B.A., and Foster, D. (2020). LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv.","DOI":"10.1101\/2020.09.30.318972"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Mahase, E. (2020). Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients. BMJ, 371.","DOI":"10.1136\/bmj.m4362"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kaplon, H., and Reichert, J.M. (2021). Antibodies to watch in 2021. MAbs, 13.","DOI":"10.1080\/19420862.2020.1860476"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S., Reynoso, L., Downey, G.P., and Frankel, S.K. (2021). 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. bioRxiv.","DOI":"10.1101\/2021.02.16.431305"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: An update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_49","first-page":"84","article-title":"Sensitivity of Various Influenza Virus Strains to Arbidol. Influence of Arbidol Combination With Different Antiviral Drugs on Reproduction of Influenza Virus A","volume":"77","author":"Leneva","year":"2005","journal-title":"Ter. Arkh."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.bmc.2005.11.033","article-title":"Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3-carboxylates","volume":"14","author":"Zhao","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Boriskin, Y.S., P\u00e9cheur, E.I., and Polyak, S.J. (2006). Arbidol: A broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol. J., 3.","DOI":"10.1186\/1743-422X-3-56"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00063198-200405000-00009","article-title":"Antiviral chemotherapeutic agents against respiratory viruses: Where are we now and what\u2019s in the pipeline?","volume":"10","author":"Brooks","year":"2004","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/j.1460-2075.1982.tb01150.x","article-title":"Membrane fusion activity of influenza virus","volume":"1","author":"White","year":"1982","journal-title":"EMBO J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jmv.22234","article-title":"Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions","volume":"84","author":"Brooks","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","article-title":"The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses","volume":"90","author":"Borisevich","year":"2016","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1128\/JVI.00253-07","article-title":"Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted","volume":"81","author":"Inoue","year":"2007","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen, S.D., Jin, H.J., Tan, K.S., Wang, D.Y., and Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil. Med. Res., 7.","DOI":"10.1186\/s40779-020-00240-0"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Vankadari, N. (2020). Arbidol: A potential antiviral drug for the treatment of SARS- CoV-2 by blocking trimerization of the spike glycoprotein. Int. J. Antimicrob. Agents, 56.","DOI":"10.1016\/j.ijantimicag.2020.105998"},{"key":"ref_60","first-page":"289","article-title":"Efficacy and safety of arbidol in treatment of naturally acquired influenza","volume":"26","author":"Wang","year":"2004","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: A retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J. Infect."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430-A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Elfiky, A.A. (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci., 253.","DOI":"10.1016\/j.lfs.2020.117592"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003495-199856010-00013","article-title":"Nelfinavir. A review of its therapeutic efficacy in HIV infection","volume":"56","author":"Jarvis","year":"1998","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/aid.1992.8.153","article-title":"The HIV-1 protease as a therapeutic target for AIDS","volume":"8","author":"Debouck","year":"1992","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_70","first-page":"325","article-title":"Nelfinavir mesylate: A protease inhibitor","volume":"33","author":"Pai","year":"1999","journal-title":"Ann. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/AAC.01295-10","article-title":"The HIV protease inhibitor nelfinavir inhibits Kaposi\u2019s sarcoma-associated herpesvirus replication in vitro","volume":"55","author":"Gantt","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1128\/JVI.03790-13","article-title":"Nelfinavir inhibits maturation and export of herpes simplex virus 1","volume":"88","author":"Kalu","year":"2014","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhang, J., Wang, N., Li, H., Shi, Y., Guo, G., Liu, K., Zeng, H., and Zou, Q. (2020). Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. bioRxiv, in press.","DOI":"10.1101\/2020.01.28.922922"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Cardoso, W.B., and Mendanha, S.A. (2021). Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors. J. Mol. Struct., 1225.","DOI":"10.1016\/j.molstruc.2020.129143"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/jmv.25985","article-title":"The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19","volume":"92","author":"Musarrat","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/13543784.7.8.1313","article-title":"Saquinavir-soft gel: Establishing saquinavir in HAART regimens","volume":"7","author":"Moyle","year":"1998","journal-title":"Expert Opin. Investig. Drug"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003495-199652010-00007","article-title":"Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection","volume":"52","author":"Noble","year":"1996","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003088-199834030-00002","article-title":"Saquinavir. Clinical pharmacology and efficacy","volume":"34","author":"Vella","year":"1998","journal-title":"Clin. Pharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"F29","DOI":"10.1097\/00002030-199704000-00001","article-title":"Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients","volume":"11","author":"Merry","year":"1997","journal-title":"AIDS"},{"key":"ref_81","first-page":"423","article-title":"Cytochrome P450- mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes","volume":"277","author":"Kumar","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003495-199855030-00014","article-title":"Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection","volume":"55","author":"Perry","year":"1998","journal-title":"Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jcv.2005.03.005","article-title":"Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza","volume":"34","author":"Savarino","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10096-005-0004-z","article-title":"Treatment of severe acute respiratory syndrome","volume":"24","author":"Lai","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_85","first-page":"400","article-title":"Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target","volume":"19","author":"Ortega","year":"2020","journal-title":"EXCLI J."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Hall, D.C., and Ji, H.F. (2020). A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med. Infect. Dis., 35.","DOI":"10.1016\/j.tmaid.2020.101646"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Khan, S.A., Zia, K., Ashraf, S., Uddin, R., and Ul-Haq, Z. (2021). Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J. Biomol. Struct. Dyn., in press.","DOI":"10.1080\/07391102.2020.1751298"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., and Deval, J. (2013). The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068347"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/nature08260","article-title":"In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses","volume":"460","author":"Itoh","year":"2009","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., and Lu, M. (2020). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Tchesnokov, E.P., Feng, J.Y., Porter, D.P., and G\u00f6tte, M. (2019). Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses, 11.","DOI":"10.3390\/v11040326"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., Smith, E.C., Case, J.B., Feng, J.Y., and Jordan, R. (2018). Coronavirus Susceptibility to the Antiviral Remdesivir (GS- 5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio, 9.","DOI":"10.1128\/mBio.00221-18"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Ko, W.C., Rolain, J.M., Lee, N.Y., Chen, P.L., Huang, C.T., Lee, P.I., and Hsueh, P.R. (2020). Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int. J. Antimicrob. Agents, 55.","DOI":"10.1016\/j.ijantimicag.2020.105933"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Lo, M.K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A.L., Flint, M., McMullan, L.K., Siegel, D., and Clarke, M.O. (2017). GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep., 7.","DOI":"10.1038\/srep43395"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B., Leist, S.R., Pyrc, K., Feng, J.Y., and Trantcheva, I. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aal3653"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Tu, Y.F., Chien, C.S., Yarmishyn, A.A., Lin, Y.Y., Luo, Y.H., Lin, Y.T., Lai, W.Y., Yang, D.M., Chou, S.J., and Yang, Y.P. (2020). A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072657"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate Use of Remdesivir for Patients with Severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/phar.2403","article-title":"Delayed Initiation of Remdesivir in a COVID-19-Positive Patient","volume":"40","author":"Hillaker","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MCP.0b013e3282f79651","article-title":"Respiratory syncytial virus infection in adults","volume":"14","author":"Murata","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin\u2014Current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000237969","article-title":"Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection","volume":"27","author":"Bierman","year":"1981","journal-title":"Chemotherapy"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Habib, A.M.G., Ali, M.A.E., Zouaoui, B.R., Taha, M.A.H., Mohammed, B.S., and Saquib, N. (2019). Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4555-5"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus- associated SARS pneumonia: A prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa030685","article-title":"A major outbreak of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa030634","article-title":"Identification of severe acute respiratory syndrome in Canada","volume":"348","author":"Poutanen","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study","volume":"14","author":"Omrani","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Sundquist, W.I., and Kr\u00e4usslich, H.G. (2012). HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med., 2.","DOI":"10.1101\/cshperspect.a015420"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: Initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"Jochmans","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Choy, K.T., Wong, A.Y., Kaewpreedee, P., Sia, S.F., Chen, D., Hui, K., Chu, D., Chan, M., Cheung, P.P., and Huang, X. (2020). Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir. Res., 178.","DOI":"10.1016\/j.antiviral.2020.104786"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Muralidharan, N., Sakthivel, R., Velmurugan, D., and Gromiha, M.M. (2021). Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J. Biomol. Struct. Dyn., in press.","DOI":"10.1080\/07391102.2020.1752802"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMe2005477","article-title":"Covid-19-The Search for Effective Therapy","volume":"382","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: Recent insights into emerging coronaviruses","volume":"14","author":"Falzarano","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_124","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1248\/bpb.28.399","article-title":"Sialobiology of influenza: Molecular mechanism of host range variation of influenza viruses","volume":"28","author":"Suzuki","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2004.08.012","article-title":"Assembly and budding of influenza virus","volume":"106","author":"Nayak","year":"2004","journal-title":"Virus Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1128\/JVI.78.22.12665-12667.2004","article-title":"Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium","volume":"78","author":"Matrosovich","year":"2004","journal-title":"J. Virol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"9133","DOI":"10.1002\/jcp.29785","article-title":"A global treatments for coronaviruses including COVID-19","volume":"235","author":"Yousefi","year":"2020","journal-title":"J. Cell Physiol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/6\/503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:21Z","timestamp":1760162841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/6\/503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":130,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ph14060503"],"URL":"https:\/\/doi.org\/10.3390\/ph14060503","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}